Windward Bio to Participate at the Jefferies London Global Healthcare Conference
Globe Newswire•17/11/2026•16:01 ET
0
Key Highlights
- ➤Windward management to present at Jefferies London Global Healthcare Conference November 18
- ➤WIN378 Phase 2/3 POLARIS-1 study evaluates severe uncontrolled asthma
- ➤WIN378 Phase 2 SIRIUS study evaluates COPD
- ➤WIN027 Phase 1 study evaluates TSLP and IL-13 bispecific antibody
BASEL, Switzerland, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced that members of management will present at the Jefferies London Global Healthcare Conference on Wednesday, November 18, 2026, at 8:30 a.m.GMT.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Windward Bio website.
Get started
Create a free account to read the full story.
